Patients in Lenvatinib + TACE group will take oral lenvatinib within one day of randomization and receive TACE 1 day after oral administration of lenvatinib.

Patients in Sorafenib + TACE group will take oral sorafenib within one day of randomization and receive TACE 1 day after oral administration of lenvatinib.

Carcinoma, Hepatocellular

Portal Vein Tumor Thrombus

Lenvatinib capsules will be admministered orally, once daily in continuous 28-day cycles. Body weight (BW)＞60 kilograms(kg)-Lenvatinib 12 mg (taken as three 4-mg capsules); BW＜60kg-Lenvatinib 8 mg (taken as two 4-mg capsules)

Lenvatinib Pill

TACE will be performed one day after oral administration of lenvatinib . TACE with either cTACE or DEB-TACE can be used, depending on the condition of center.

Transarterial chemoembolization(TACE)

Sorafenib capsules will be admministered orally, 400 mg twice daily (BID) oral dosing.

Sorafenib

TACE will be performed one day after oral administration of Sorafenib. TACE with either cTACE or DEB-TACE can be used, depending on the condition of center.

Beijing Ditan Hospital, Capital Medical University

Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT

Exploring Lenvatinib Plus TACE Versus Sorafenib Plus TACE for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: Efficacy, Safety and Outcome Analysis

The primary endpoint was TTP (defined as the date of randomization until progression).
Treatment response was evaluated according to mRECIST combined with contrast-enhanced dynamic CT or magnetic resonance imaging.

ORR defined as the rate of patients with complete response or partial response according to mRECIST.

OS defined as the date of randomization to death from any cause.

AEs(adverse events) evaluated by the CTC-AE 5.0.

Jinglong Chen

Chief of Oncology

Beijing Ditan Hospital

400 patients with primary HCC (Hepatocellular carcinoma)

800 patients with chronic liver disease (high risk non-cancer cases)

800 population-based controls, identified through a OMV database that will match cases by age, gender, race, and county of residency

Blood and tissue samples, mouth wash and urine.

liver neoplasms/nikotiin

Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT

A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area

Genes Involved in Resistance or Susceptibility to Hepatitis B Virus

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus